Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1999

View Archived Issues

Company Profile: Cangene

Immunomedics seeks EMEA approval for CEA-Scan

Phase II study initiated by Neose for otitis media prevention

Inflazyme updates shareholders

Cell Genesys: Q4 and year-end 1998 highlights

Nicotinic acetylcholine receptor agonists emerge from Sumitomo R&D

SB patents new cathepsin K inhibitors

Novel triptolide derivatives from HMR for rheumatoid arthritis and other autoimmune diseases

Novel cognition-enhancing agents designed at MS&D

Orally active inhibitors of tumor neovascularization described by Mercian

Recently issued U.S. patent covers new D4 receptor ligands developed at Merck Sharp & Dohme

UPSA reveals potent, orally active and well-tolerated antiinflammatory/analgesic agents

OP-1 protects against cerebral infarct in rat model

Novel piperazine hydroxyethylamine HIV protease inhibitor shows promise in preclinical studies

Another lipid-lowering statin now on the market in Argentina

Structurally novel dimeric steroid with cytotoxic activity isolated from marine sponge

Digene reports advances in papillomavirus diagnosis

Small Molecule Therapeutics identifies antibacterial class of compounds

Deltagen enters another gene target validation collaboration

Shaman reviews filing strategy for SP-303 following pre-NDA meeting with FDA

OSI diagnostic subsidiary will develop test to detect childhood cancer

Three patents covering drug formulation technology issued to Delsys

Angiotech to study paclitaxel for yet another new indication

Anti-TNF MAb reduces circulating levels of sPLA2 in Crohn's disease patients

Carrington announces plans for phase III testing of Aliminase

Licensing opportunity from NIH: methods of treating inflammation

Dietary therapy of rheumatoid arthritis evaluated in six-month controlled trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...